AstraZeneca And Astellas Enter Agreement for Co-Advertising of Symbicort Turbuhaler in Japan Astellas and AstraZeneca Pharma Inc. Announced an contract for the co-advertising of AstraZeneca’s Symbicort Turbuhaler , for the treating bronchial asthma in Japan. Beneath the agreement, Astellas and AstraZeneca will co-promote Symbicort Turbuhaler and Astellas will lead to distribution of the merchandise possible-impotence-causes.html .0 billion based on the accomplishment of certain product sales and authorization of yet another indication by japan authority. Symbicort Turbuhaler isn’t available in Japan. AstraZeneca submitted a fresh drug program in Japan in-may, 2007. The outcome of the submission is anticipated in the 4th quarter of 2009.
Asthma research business Synairgen to float on London’s Alternative Investment Market A spin-out business from the University of Southampton specialising to find and out-licensing remedies for chronic bronchitis and the severest types of asthma, is going to seek an inventory on London’s Alternative Expenditure Market . World-famous scientist Professor Stephen Holgate and his co-workers Dr Ratko Djukanovic and Dr Donna Davies, who founded Synairgen in the summertime of 2003, possess spent a long time researching the underlying mechanisms of respiratory disease and provide that experience to the business. The team’s function culminated in the discovery of a individual gene important to the advancement of asthma. The business is already focusing on three collaborations with worldwide drug companies and, with the University of Southampton, provides filed two patents.